SRNE — Sorrento Therapeutics Balance Sheet
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.50m
- $69.12m
- $62.84m
Annual balance sheet for Sorrento Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 159 | 22.5 | 56.5 | 127 | 50 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4.36 | 14.5 | 15.5 | 18.7 | 24.5 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 180 | 67.6 | 86.2 | 173 | 96.4 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 24.4 | 76.3 | 73.9 | 126 | 138 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 624 | 558 | 536 | 695 | 473 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 61.6 | 115 | 96.5 | 139 | 328 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 415 | 479 | 371 | 616 | 491 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 209 | 78.6 | 165 | 78.7 | -18.6 |
Total Liabilities & Shareholders' Equity | 624 | 558 | 536 | 695 | 473 |
Total Common Shares Outstanding |